Rineterkib is primarily investigated for its potential in cancer therapy, specifically as a targeted treatment in oncology. It functions by inhibiting specific kinase enzymes involved in tumor cell proliferation and survival. This compound shows promise in disrupting signaling pathways that drive the growth of certain cancers, particularly those with defined genetic mutations. Its application is focused on advanced-stage clinical trials evaluating efficacy and safety in patients with solid tumors, especially where standard treatments have failed. Due to its mechanism, rineterkib may offer a personalized medicine approach, benefiting patients with specific biomarker profiles. Research continues to explore optimal dosing, combination therapies, and long-term clinical outcomes.